TWO METHODS OF ORAL DELIVERY OF RESVERATROL: A CASE STUDY

Background: Resveratrol is one of the most popular nutrition supplements, especially in the older population segment, yet its safety and health benefits are not fully established. This study aimed at determining bioavailability and the physiological effects of resveratrol delivered by 2 methods in a one senior patient case study. Methods: Bioavailability of resveratrol and blood chemistry parameters following the gastrointestinal and transbuccal intake were measured, respectively, by HPLC in blood and urine, and by blood chemistry analyzer. Results: The fraction of the initially administered resveratrol detected in the blood was over 15 times higher following transbuccal intake than through the gastrointestinal tract. About 36% of the ingested resveratrol was excreted in urine as 3 major metabolites, while only 11% were secreted as major metabolites following the transbuccal intake. The major metabolite in urine peaked at the same time regardless of the method of delivery. Three long-term (31 day) cycles of resveratrol supplementation by transbuccal mucoadhesive film or by ingestion did not result in any noticeable (over 5%) variation of blood chemistry, blood pressure or the overall physical condition of the patient. Conclusion: Bioavailability of resveratrol delivered through oral mucosa may be over one log higher than by swallowing, as determined by the fraction of the initial resveratrol intake in the blood and, under metabolized form, in urine. Lack of resveratrol-associated changes in blood pressure and chemistry following long term supplementation demonstrates good tolerance to high doses of resveratrol in this senior patient case study.